161 related articles for article (PubMed ID: 29323063)
1. Evaluation of MUC1 and P53 expressions in noninvasive papillary urothelial neoplasms of bladder, their relationship with tumor grade and role in the differential diagnosis.
Kaymaz E; Ozer E; Unverdi H; Hucumenoglu S
Indian J Pathol Microbiol; 2017; 60(4):510-514. PubMed ID: 29323063
[TBL] [Abstract][Full Text] [Related]
2. Expression of MUC1 (Ma695) in noninvasive papillary urothelial neoplasm according to the 2004 World Health Organization classification of the noninvasive urothelial neoplasm. An immunologic tool for the pathologist?
Garbar C; Mascaux C
Anal Quant Cytol Histol; 2011 Oct; 33(5):277-82. PubMed ID: 22611755
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms.
Qi G; Liu J; Tao S; Fan W; Zheng H; Wang M; Yang H; Liu Y; Liu H; Zhou F
PeerJ; 2023; 11():e15675. PubMed ID: 37456895
[TBL] [Abstract][Full Text] [Related]
4. Cytologic diagnosis of low-grade papillary urothelial neoplasms (low malignant potential and low-grade carcinoma) in the context of the 1998 WHO/ISUP classification.
Whisnant RE; Bastacky SI; Ohori NP
Diagn Cytopathol; 2003 Apr; 28(4):186-90. PubMed ID: 12672093
[TBL] [Abstract][Full Text] [Related]
5. Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT: Comparative Analyses with Noninvasive Low-Grade Papillary Urothelial Carcinoma (LGPUC).
Kim JK; Moon KC; Jeong CW; Kwak C; Kim HH; Ku JH
J Cancer; 2017; 8(15):2885-2891. PubMed ID: 28928878
[No Abstract] [Full Text] [Related]
6. Immunohistochemical expression of p63, p53 in urinary bladder carcinoma.
Koyuncuer A
Indian J Pathol Microbiol; 2013; 56(1):10-5. PubMed ID: 23924551
[TBL] [Abstract][Full Text] [Related]
7. Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility.
Tuna B; Yörükoglu K; Düzcan E; Sen S; Nese N; Sarsık B; Akder A; Sayhan S; Mungan U; Kirkali Z
Virchows Arch; 2011 Jun; 458(6):659-64. PubMed ID: 21484429
[TBL] [Abstract][Full Text] [Related]
8. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
Kalantari MR; Ahmadnia H
Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer.
Jones TD; Cheng L
Urol Oncol; 2021 May; 39(5):286-290. PubMed ID: 35550107
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression profiles of MUC1 and MUC2 mucins in urothelial tumors of bladder.
Gonul II; Cakir A; Sozen S
Indian J Pathol Microbiol; 2018; 61(3):350-355. PubMed ID: 30004053
[TBL] [Abstract][Full Text] [Related]
11. MOLECULAR CHARACTERISTICS OF THE HETEROGENEITY OF NON-INVASIVE PAPILLARY UROTHELIAL CARCINOMAS AND THE MARKERS OF THEIR RECURRENCE.
Kajaia D; Kochiashvili D; Muzashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2021; (316-317):178-184. PubMed ID: 34511468
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of the papillary urothelial neoplasm of low malignant potential (PUNLMP).
Jones TD; Cheng L
Histopathology; 2020 Oct; 77(4):525-535. PubMed ID: 32562556
[TBL] [Abstract][Full Text] [Related]
13. Invasive low-grade papillary urothelial carcinoma: an immunohistochemical study of 26 cases.
Tian W; Epstein JI
Hum Pathol; 2015 Dec; 46(12):1836-41. PubMed ID: 26391571
[TBL] [Abstract][Full Text] [Related]
14. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological analysis of recurrence and progression of low-grade papillary urothelial carcinoma of the urinary bladder: Predicting the outcome.
Bahmad HF; Lopez O; Moreno JCA; Lopez K; Malik F; Salami A; Nieder AM; Omarzai Y; Poppiti RJ
Ann Diagn Pathol; 2022 Dec; 61():152030. PubMed ID: 36055007
[TBL] [Abstract][Full Text] [Related]
16. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL
J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.
Maxwell JP; Wang C; Wiebe N; Yilmaz A; Trpkov K
Diagn Pathol; 2015 Mar; 10():3. PubMed ID: 25886613
[TBL] [Abstract][Full Text] [Related]
18. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
[TBL] [Abstract][Full Text] [Related]
19. Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts.
Jones TD; Cheng L
J Urol; 2006 Jun; 175(6):1995-2003. PubMed ID: 16697785
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical comparison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact.
Sangoi AR; Higgins JP; Rouse RV; Schneider AG; McKenney JK
Mod Pathol; 2009 May; 22(5):660-7. PubMed ID: 19270645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
